Étude de phase I-II d'une radiothérapie stéréotaxique hypofractionnée par le cyberknife® pour le traitement de récidive biochimique de cancer de la prostate après un traitement de radiothérapie.
Cyberknife® prostate
 Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Prostate |
Dr. Jean-Paul Bahary
Diane Trudel
514-890-8000 poste 11181
|
The predictive value of coexisting TMPRSS2-ERG gene fusion and PTEN deletion in prostate cancer patients with biochemical failure status post salvage or radical radiation therapy
PCS VIII
NCT02573636
Recruiting
|
CISSS DE LAVAL
HOPITAL DE LA CITE-DE-LA-SANTE
|
Prostate |
Dr. Levon Igidbashian
Solange Tremblay
450-668-1010 poste 23603
|
Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial.
PCS-XI
NCT05820633
Recruiting
|
CISSS DE LAVAL
HOPITAL DE LA CITE-DE-LA-SANTE
|
Prostate |
Dr. Danny Duplan
Imane Benmouhoub
450-668-1010 poste 23671
|
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer
EvoPAR-Prostate01
NCT06120491
Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Prostate |
Dr. Catherine Sperlich
Valérie Painchaud-Lachapelle
450-466-5000 poste 2278
|
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
MK-5684-003
NCT06136624
Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Prostate |
Dr. Catherine Sperlich
Marie-Ève Yelle
450-466-5000 poste 3281
|
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer
EvoPAR-Prostate01
NCT06120491
Recruiting
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
Prostate |
Dr. Jean-Benoit Paradis
Sabrina Côté
418-541-1000 poste 3065
|
Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial.
PCS-XI
NCT05820633
Recruiting
|
CISSS DE L'OUTAOUAIS
HOPITAL DE GATINEAU
|
Prostate |
Dr. Pierre-Yves McLaughlin
Céline Roy
819-966-6100 poste 3669
|
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer
ARASTEP
NCT05794906
Recruiting
|
CISSS DE L'OUTAOUAIS
HOPITAL DE GATINEAU
|
Prostate |
Dr. Steven Tisseverasinghe
Céline Roy
819-966-6100 poste 3669
|
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
rechARge
NCT06764485
Recruiting
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Prostate |
Dr. Samuel Nadeau
Isabelle Gagnon
418-724-3000 poste 8029
|
An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of AZD5305 Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer
ASCERTAIN
NCT05938270
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Prostate |
Dr. Louis Lacombe
Marilyn Savard
418-525-4444 poste 67703
|
Groupe d'étude en oncologie du Québec